Cambridge Healthtech Institute’s Inaugural

Emerging T Cell Engagers

January 20-21, 2027

Cambridge Healthtech Institute’s Inaugural Emerging T Cell Engagers conference spotlights one of the hottest and fastest-moving areas in multispecific therapeutics. Building on the breadth of multispecific engineering themes covered in the preceding conference, this program offers a focused deep dive into T cell engagers and the design challenges shaping their next phase of development. As TCEs move deeper into solid tumors and expand beyond oncology, researchers are rethinking how to tune target engagement, improve T cell activation at the tumor site, localize immune activity, and manage cytokine-driven toxicity. The program will examine next-generation strategies across solid tumor TCEs, multisignal activation, conditional and masked formats, and costimulatory and cytokine-modulating designs, while also exploring alternative immune-engager approaches that harness NK cells, macrophages, and myeloid biology. Together, these discussions will give researchers a timely forum to examine where T cell engagers are advancing, which design challenges still need to be solved, and how TCEs may open new therapeutic opportunities in areas such as autoimmunity and I&I.

Coverage will include, but is not limited to:

NEXT-GENERATION T CELL ENGAGERS FOR SOLID TUMORS

Engineering TCEs for solid-tumor potency without excessive cytokine release
Improving solid-tumor activity: target density, avidity, geometry, and epitope selection
Conditional activation and masking approaches
Lessons from clinical successes and failures
Biologically meaningful preclinical models

MULTISIGNAL T CELL ACTIVATION: COSTIMULATION, CYTOKINES, AND ENGINEERING THE SYNAPSE

CD28, 4-1BB/CD137, CD2, cytokine, and checkpoint-modulating arms in TCE and trispecific formats
Localizing costimulation to the TME
Built-in trispecific costimulation versus companion engagers or combination strategies
Engineering immune synapse formation, activation thresholds, and signal strength for durable responses
Balancing efficacy, T cell exhaustion, and cytokine release

BEYOND TCEs: NK, MACROPHAGE, AND MYELOID ENGAGERS

NK cell, macrophage, and myeloid engagers: design principles and indication fit
Combining innate and adaptive immune engagement

T CELL ENGAGERS IN AUTOIMMUNITY AND I&I

Liquid tumor TCE learnings applied to autoimmune disease:
- CD19 and CD20 TCEs
Promising TCEs for I&I
Novel non-oncology TCE targets
Biologically meaningful preclinical models

The deadline for priority consideration is June 26, 2026.

All proposals are subject to review by session chairpersons and/or the Scientific Advisory Committee to ensure the overall quality of the conference program. Additionally, as per Cambridge Healthtech Institute’s policy, a select number of vendors and consultants who provide products and services will be offered opportunities for podium presentation slots based on a variety of Corporate Sponsorships.

Opportunities for Participation: